A UK research team has developed a pioneering blood test that could change the way lung cancer is detected and monitored.
NeXT Personal identifies circulating tumor DNA in 81% of early-stage lung adenocarcinoma cases, offering potential for better disease stratification and outcome prediction. Study: Ultrasensitive ctDNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback